leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...152153154155156157158159160161162...235236»
  • ||||||||||  oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    [VIRTUAL] A single-centre experience of adjuvant oxaliplatin based chemotherapy in elderly stage II-III colorectal cancer patients () -  May 13, 2020 - Abstract #ESMOGI2020ESMO_GI_362;    
    Background The MOSAIC trial showed the benefit of adding oxaliplatin to fluorouracil plus leucovorin with a 78.2% 3-year survival, however, patients > 75 years old were not included...Results 108 patients were identified, 63 receiving doublet chemotherapy (FOLFOX and CAPOX) and 45 receiving single-agent chemotherapy (Capecitabine or modified de Gramont)...Legal entity responsible for the study The authors. Funding Has not received any funding.
  • ||||||||||  leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    [VIRTUAL] The outcomes and toxicity of FOLFIRINOX treatment in a cohort of patients with incurable pancreatic cancer treated in a single centre in Northern Ireland () -  May 13, 2020 - Abstract #ESMOGI2020ESMO_GI_358;    
    Background The ACCORD 11 trial demonstrated the superiority of FOLFIRINOX over Gemcitabine monotherapy in patients with metastatic pancreatic cancer, with minimal co-morbidities and an ECOG performance status of 0 or 1...Methods Patients who received FOLFIRINOX (Irinotecan 180mg/m2 , Oxaliplatin 80mg/m2 , Folinic acid 200mg/m2 and 5FU infusion 2400mg/m2 over 46 hours) for advanced pancreatic cancer between 2010 and 2019 in the Northern Ireland Cancer Centre, were identified from the oncology information system...Legal entity responsible for the study The author. Funding Has not received any funding.
  • ||||||||||  [VIRTUAL] HGCSG1801: A phase II trial of 2nd-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibody () -  May 13, 2020 - Abstract #ESMOGI2020ESMO_GI_260;    
    Anti-angiogenic inhibitors (bevacizumab, ramucirumab, and aflibercept beta (AFL)) showed survival benefit combined with FOLFIRI as second-line chemotherapy in randomized controlled trials...Therefore, we planned a phase II trial of second-line FOLFIRI plus aflibercept in patients with mCRC refractory to oxaliplatin-based chemotherapy combined with anti-EGFR antibody...FOLFIRI (irinotecan 180mg/m2 , l-leucovorin 200mg/m2 , bolus 5-FU 400mg/m2 and infusional 5-FU 2400mg/m2 /46hrs) and AFL 4mg/kg are administered every 2 weeks until progression or unacceptable toxicities...Legal entity responsible for the study The authors. Funding Sanofi.
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Trial completion date, Trial primary completion date:  NOM-ERA: Non-Operative Management and Early Response Assessment in Rectal Cancer (clinicaltrials.gov) -  May 12, 2020   
    P=N/A,  N=68, Not yet recruiting, 
    Active, not recruiting --> Recruiting | Trial completion date: Dec 2022 --> Nov 2021 Trial completion date: Mar 2025 --> Jul 2025 | Trial primary completion date: Sep 2023 --> Jan 2024
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Avastin (bevacizumab) / Roche
    Trial completion date, Metastases:  HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC (clinicaltrials.gov) -  May 12, 2020   
    P2,  N=32, Not yet recruiting, 
    Trial completion date: Mar 2025 --> Jul 2025 | Trial primary completion date: Sep 2023 --> Jan 2024 Trial completion date: Jun 2022 --> May 2023
  • ||||||||||  methylphenidate tablet / Generic mfg.
    Retrospective data, Review, Journal:  Meta-analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders. (Pubmed Central) -  May 12, 2020   
    The results of the present meta-analysis suggest that currently available pharmacological agents have at best only a modest benefit for the treatment of RRB in ASD, with the most evidence supporting antipsychotic medications. Additional randomized controlled trials with standardized study designs and consistent and specific assessment tools for RRB are needed to further understand how we can best help ameliorate these behaviors in individuals with ASD.
  • ||||||||||  oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
    Journal:  miR-124 Intensified Oxaliplatin-Based Chemotherapy by Targeting CAPN2 in Colorectal Cancer. (Pubmed Central) -  May 10, 2020   
    miR-124 also promoted L-OHP-induced apoptosis and restrained CAPN2 protein expression in xenograft tumors. Our results suggest that miR-124 could be considered as both a predictor of L-OHP-based chemotherapy for personalized treatment and a therapeutic target for CRC.
  • ||||||||||  fluorouracil topical / Generic mfg., Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda, PharmaEngine
    Clinical, Journal, HEOR:  Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin. (Pubmed Central) -  May 7, 2020   
    P3
    Gemcitabine alone did not show meaningful clinical benefit as second-line treatment after FOLFIRINOX. In the NAPOLI-1 study, HRQOL was maintained with nal-IRI+5-FU/LV in patients with metastatic pancreatic adenocarcinoma previously treated with a gemcitabine-based regimen, while survival was significantly extended.
  • ||||||||||  leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
    Journal:  Deletions in metastatic colorectal cancer with chromothripsis. (Pubmed Central) -  May 6, 2020   
    Suspended --> Active, not recruiting Multiple chromosomal deletions (MIR1269, NRG3, ADK) in mCRC patients with chromothripsis are associated with better response to first line palliative FOLFOX-type chemotherapy and increased PFS.
  • ||||||||||  Retrospective data, Journal:  Primary tumor location and survival in colorectal cancer: A retrospective cohort study. (Pubmed Central) -  May 6, 2020   
    Multiple chromosomal deletions (MIR1269, NRG3, ADK) in mCRC patients with chromothripsis are associated with better response to first line palliative FOLFOX-type chemotherapy and increased PFS. In this real-world mCRC cohort, the prognostic role of primary tumor location was substantiated, but not the predictive role for treatment with cetuximab vs bevacizumab in combination with 5-fluorouracil-based chemotherapy.
  • ||||||||||  oxaliplatin / Generic mfg.
    Enrollment closed:  Lidocaine for Oxaliplatin-induced Neuropathy (clinicaltrials.gov) -  May 6, 2020   
    P1/2,  N=38, Active, not recruiting, 
    In this real-world mCRC cohort, the prognostic role of primary tumor location was substantiated, but not the predictive role for treatment with cetuximab vs bevacizumab in combination with 5-fluorouracil-based chemotherapy. Recruiting --> Active, not recruiting
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Avastin (bevacizumab) / Roche
    Trial completion date, Trial initiation date, Trial primary completion date, Metastases:  HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC (clinicaltrials.gov) -  May 4, 2020   
    P2,  N=32, Not yet recruiting, 
    Recruiting --> Active, not recruiting Trial completion date: Jan 2022 --> Jun 2022 | Initiation date: Dec 2019 --> May 2020 | Trial primary completion date: Jan 2022 --> Jun 2022
  • ||||||||||  oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Enrollment change, Trial completion date, Real-world evidence, Real-world, Metastases:  FOTAC: FOLFOX6 Totally Neoadjuvant Chemoradiation Therapy in Locally Advanced Rectal Cancer: A Real World Study (clinicaltrials.gov) -  May 4, 2020   
    P2,  N=200, Recruiting, 
    Trial completion date: Jan 2022 --> Jun 2022 | Initiation date: Dec 2019 --> May 2020 | Trial primary completion date: Jan 2022 --> Jun 2022 N=50 --> 200 | Trial completion date: Nov 2019 --> Aug 2020
  • ||||||||||  leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
    Journal:  Mechanism of Action of Methotrexate Against Zika Virus. (Pubmed Central) -  Apr 30, 2020   
    We also found that addition of adenosine to ZIKV-infected cells was able to rescue ZIKV replication inhibited by MTX, suggesting that restriction of de novo synthesis adenosine triphosphate (ATP) pools suppresses viral replication. These results confirm that the DHFR pathway can be targeted to inhibit replication of ZIKV, similar to other published results showing this effect in related flaviviruses.
  • ||||||||||  Enrollment closed, Trial completion date:  FOLFIRINOX + RT for Pancreatic Cancer (clinicaltrials.gov) -  Apr 30, 2020   
    P2,  N=48, Active, not recruiting, 
    Recruiting --> Suspended Completed --> Active, not recruiting | Trial completion date: Jan 2019 --> Jan 2021
  • ||||||||||  Vyloy (zolbetuximab-clzb) / Astellas
    Biomarker, Trial completion date, Trial primary completion date, Monotherapy, PD(L)-1 Biomarker:  ILUSTRO: A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer (clinicaltrials.gov) -  Apr 29, 2020   
    P2,  N=112, Recruiting, 
    Completed --> Active, not recruiting | Trial completion date: Jan 2019 --> Jan 2021 Trial completion date: Jul 2020 --> Oct 2022 | Trial primary completion date: Apr 2020 --> Oct 2020
  • ||||||||||  Rituxan (rituximab) / Roche
    Enrollment change, Trial completion date, Trial primary completion date:  LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma (clinicaltrials.gov) -  Apr 29, 2020   
    P1,  N=22, Recruiting, 
    Trial completion date: Jul 2020 --> Oct 2022 | Trial primary completion date: Apr 2020 --> Oct 2020 N=12 --> 22 | Trial completion date: Oct 2020 --> Oct 2021 | Trial primary completion date: Oct 2020 --> Oct 2021
  • ||||||||||  leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
    [VIRTUAL] Evaluation of high-dose methotrexate serum concentration requirement for discharge. () -  Apr 29, 2020 - Abstract #ASCO2020ASCO_4913;    
    Results of this study will be used to a develop a standardized protocol outlining criteria for early discharge in select pts with MTX levels < 0.3 µmol/L to reduce length of stay, cost of hospitalization and improve patient satisfaction. Research Funding: None